Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label safety study of evinacumab in homozygous familial hypercholesterolemia
jRCT2051220184Completed
- Start
- Mar 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of evinacumab in homozygous familial hypercholesterolemia (HoFH). Primary endpoint: Incidence and severity of adverse events. Started Mar 2023; status: completed.
02
Drugs
evinacumab
03
Conditions
homozygous familial hypercholesterolemia (HoFH)
Beyond the preview
Go deeper on jRCT2051220184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051220184.